Israeli company Vaxil Biotherapeutics, which is developing vaccines for cancer and tuberculosis, has received a $3 million investment. The investment was made by Yorkville Advisors, which will transfer the funds over the next five years.
Vaxil was founded in late 2006 and is headquartered at the Weizmann Science Park.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023

Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023

Solar Panels On A Roll Certified As Safe For Use In US, Europe
September 28, 2023

US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023
Facebook comments